Management of Hypertrophic Cardiomyopathy
Background: Hypertrophic cardiomyopathy (HCM) is clinically defined as unexplained myocardial hypertrophy, and it is an autosomal dominant disease of the cardiac sarcomere. It is present in 1 in 500 in the general adult population, making it the most common genetic cardiovascular disease. The pathop...
Guardado en:
Autores principales: | Alan D. Enriquez, Martin E. Goldman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Ubiquity Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf3cb7ecb20e4a078b8f7c403c1ad179 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of alcohol septal ablation in patients over 65 years old with obstructive hypertrophic cardiomyopathy
por: Cheddadi L, et al.
Publicado: (2017) -
Right Ventricular Endocardial Mapping and a Potential Arrhythmogenic Substrate in Cardiac Amyloidosis—Role of ICD
por: Aleksandra Liżewska-Springer, et al.
Publicado: (2021) -
Implantable cardioverter defibrillators: Uses, abuses, gains and complications
por: Weiwei Li, et al.
Publicado: (2017) -
Atrioventricular nodal ablation and left bundle branch pacing for treatment of refractory atrial fibrillation post alcohol septal ablation for hypertrophic obstructive cardiomyopathy
por: Rory Gallen, MB, BcH, BAO, et al.
Publicado: (2021) -
Wearable Cardioverter-Defibrillator Used as a Telemonitoring System in a Real-Life Heart Failure Unit Setting
por: Christian Blockhaus, et al.
Publicado: (2021)